Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Mersana Therapeutics buy Truist Financial Co.

Start price
€5.00
29.02.24 / 50%
Target price
€8.30
28.02.25
Performance (%)
-45.32%
Price
€2.73
26.04.24
Summary
This prediction is currently active. Massive losses of -45.32% have been the result for the BUY prediction by Truist_Financial_Co_. This prediction currently runs until 28.02.25. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this prediction
Performance without dividends (%)
Name 1w 1m
Mersana Therapeutics -10.507% -10.507%
iShares Core DAX® 2.594% -1.158%
iShares Nasdaq 100 3.553% -1.727%
iShares Nikkei 225® 0.687% -8.354%
iShares S&P 500 2.209% -0.942%

Comments by Truist_Financial_Co_ for this prediction

In the thread Mersana Therapeutics diskutieren
Prediction Buy
Perf. (%) -45.32%
Target price 8.295
Change
Ends at 28.02.25

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat